Boston Scientific Corporation (BSX) Downgraded to Hold by Argus Research

Market Context

Boston Scientific Corporation operates in the Healthcare sector. The stock currently trades at $45.16 with a market capitalization of $136.0B. The stock has declined 53.6% over the past 52 weeks.

Analyst downgrades can weigh on a stock in the short term as institutional investors who follow Argus Research's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Boston Scientific Corporation

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 31, 2026	Argus Research	Hold	N/A
Jul 30, 2026	Evercore ISI Group	Outperform	N/A
Jul 30, 2026	Wells Fargo	Equal-Weight	N/A
Jul 30, 2026	UBS	Buy	N/A
Jul 30, 2026	Truist Securities	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View BSX Stock Page